First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

NCT01646450 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Icotinib

Sponsor

Betta Pharmaceuticals Co., Ltd.